(CVS) CVS Health - Ratings and Ratios
Insurance, Pharmacy, Health Products, Medical Services, Wellness
CVS EPS (Earnings per Share)
CVS Revenue
Description: CVS CVS Health
CVS Health Corporation is a multifaceted healthcare company operating in the United States, with a presence in health insurance, pharmacy benefit management, and retail pharmacy. The companys diversified business model is structured around three main segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.
The Health Care Benefits segment offers a range of health insurance products, including medical, pharmacy, dental, and behavioral health plans, serving various clients such as employer groups, individuals, and government-sponsored plans. This segments offerings, such as Medicare Advantage and Medicare Supplement plans, position CVS Health to capitalize on the growing demand for healthcare services among the aging population.
From a strategic perspective, CVS Healths integration of health insurance and pharmacy benefit management through its Health Care Benefits and Health Services segments enables the company to offer comprehensive healthcare solutions. Key Performance Indicators (KPIs) that could be used to evaluate the success of this strategy include the medical loss ratio (MLR), customer retention rates, and the growth rate of Medicare Advantage and Medicare Supplement plans.
The Pharmacy & Consumer Wellness segment, with its extensive retail pharmacy network and online presence, is well-positioned to benefit from the shift towards more personalized and convenient healthcare services. Relevant KPIs for this segment could include same-store sales growth, the percentage of sales from digital channels, and customer satisfaction ratings.
To assess CVS Healths financial health and profitability, key metrics such as revenue growth, operating margin, return on equity (RoE), and debt-to-equity ratio are essential. With a RoE of 6.98%, the company demonstrates a reasonable return on shareholders equity. Other important metrics include the price-to-earnings (P/E) ratio of 15.66 and the forward P/E of 11.34, which indicate the markets expectations for the companys future earnings growth.
Overall, CVS Healths diversified business model, strategic positioning in growing healthcare markets, and focus on integrated healthcare solutions position the company for long-term success. Continuous monitoring of key performance indicators and market trends will be crucial in evaluating the companys progress and making informed investment decisions.
CVS Stock Overview
| Market Cap in USD | 91,231m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1984-12-17 |
CVS Stock Ratings
| Growth Rating | 31.0% |
| Fundamental | 55.9% |
| Dividend Rating | 68.4% |
| Return 12m vs S&P 500 | 12.0% |
| Analyst Rating | 4.21 of 5 |
CVS Dividends
| Dividend Yield 12m | 3.97% |
| Yield on Cost 5y | 5.04% |
| Annual Growth 5y | 5.87% |
| Payout Consistency | 94.9% |
| Payout Ratio | 42.0% |
CVS Growth Ratios
| Growth Correlation 3m | 24.9% |
| Growth Correlation 12m | 66.6% |
| Growth Correlation 5y | -31.2% |
| CAGR 5y | 6.47% |
| CAGR/Max DD 5y | 0.11 |
| Sharpe Ratio 12m | 1.12 |
| Alpha | 18.21 |
| Beta | 0.695 |
| Volatility | 30.26% |
| Current Volume | 5193.1k |
| Average Volume 20d | 5686.3k |
| Stop Loss | 69.9 (-3.1%) |
| Signal | 1.13 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (4.53b TTM) > 0 and > 6% of Revenue (6% = 23.20b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -4.79% (prev -3.15%; Δ -1.64pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 7.57b > Net Income 4.53b (YES >=105%, WARN >=100%) |
| Net Debt (70.94b) to EBITDA (10.60b) ratio: 6.69 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.27b) change vs 12m ago 0.87% (target <= -2.0% for YES) |
| Gross Margin 13.82% (prev 14.70%; Δ -0.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 151.4% (prev 143.9%; Δ 7.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.33 (EBITDA TTM 10.60b / Interest Expense TTM 3.06b) >= 6 (WARN >= 3) |
Altman Z'' 1.19
| (A) -0.07 = (Total Current Assets 75.65b - Total Current Liabilities 94.16b) / Total Assets 258.34b |
| (B) 0.25 = Retained Earnings (Balance) 63.94b / Total Assets 258.34b |
| (C) 0.03 = EBIT TTM 7.14b / Avg Total Assets 255.41b |
| (D) 0.63 = Book Value of Equity 114.23b / Total Liabilities 180.79b |
| Total Rating: 1.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 55.86
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 3.23% = 1.62 |
| 3. FCF Margin 1.24% = 0.31 |
| 4. Debt/Equity 0.88 = 2.12 |
| 5. Debt/Ebitda 6.45 = -2.50 |
| 6. ROIC - WACC -1.51% = -1.89 |
| 7. RoE 5.95% = 0.50 |
| 8. Rev. Trend 92.94% = 4.65 |
| 9. Rev. CAGR 7.46% = 0.93 |
| 10. EPS Trend 24.94% = 0.62 |
| 11. EPS CAGR 35.60% = 2.50 |
What is the price of CVS shares?
Over the past week, the price has changed by +0.99%, over one month by +20.96%, over three months by +16.78% and over the past year by +31.81%.
Is CVS Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CVS is around 71.11 USD . This means that CVS is currently overvalued and has a potential downside of -1.43%.
Is CVS a buy, sell or hold?
- Strong Buy: 13
- Buy: 8
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.3 | 12.7% |
| Analysts Target Price | 81.3 | 12.7% |
| ValueRay Target Price | 76.9 | 6.5% |
Last update: 2025-08-29 04:35
CVS Fundamental Data Overview
CCE Cash And Equivalents = 11.79b USD (last quarter)
P/E Trailing = 20.0362
P/E Forward = 12.4069
P/S = 0.2374
P/B = 1.179
P/EG = 0.7429
Beta = 0.588
Revenue TTM = 386.64b USD
EBIT TTM = 7.14b USD
EBITDA TTM = 10.60b USD
Long Term Debt = 57.29b USD (from longTermDebt, last quarter)
Short Term Debt = 11.11b USD (from shortTermDebt, last quarter)
Debt = 68.40b USD (Calculated: Short Term 11.11b + Long Term 57.29b)
Net Debt = 70.94b USD (from netDebt column, last quarter)
Enterprise Value = 147.84b USD (91.23b + Debt 68.40b - CCE 11.79b)
Interest Coverage Ratio = 2.33 (Ebit TTM 7.14b / Interest Expense TTM 3.06b)
FCF Yield = 3.23% (FCF TTM 4.78b / Enterprise Value 147.84b)
FCF Margin = 1.24% (FCF TTM 4.78b / Revenue TTM 386.64b)
Net Margin = 1.17% (Net Income TTM 4.53b / Revenue TTM 386.64b)
Gross Margin = 13.82% ((Revenue TTM 386.64b - Cost of Revenue TTM 333.19b) / Revenue TTM)
Tobins Q-Ratio = 1.29 (Enterprise Value 147.84b / Book Value Of Equity 114.23b)
Interest Expense / Debt = 1.12% (Interest Expense 763.0m / Debt 68.40b)
Taxrate = 25.41% (from yearly Income Tax Expense: 1.56b / 6.15b)
NOPAT = 5.33b (EBIT 7.14b * (1 - 25.41%))
Current Ratio = 0.80 (Total Current Assets 75.65b / Total Current Liabilities 94.16b)
Debt / Equity = 0.88 (Debt 68.40b / last Quarter total Stockholder Equity 77.38b)
Debt / EBITDA = 6.45 (Net Debt 70.94b / EBITDA 10.60b)
Debt / FCF = 14.31 (Debt 68.40b / FCF TTM 4.78b)
Total Stockholder Equity = 76.20b (last 4 quarters mean)
RoA = 1.75% (Net Income 4.53b, Total Assets 258.34b )
RoE = 5.95% (Net Income TTM 4.53b / Total Stockholder Equity 76.20b)
RoCE = 5.35% (Ebit 7.14b / (Equity 76.20b + L.T.Debt 57.29b))
RoIC = 3.75% (NOPAT 5.33b / Invested Capital 141.95b)
WACC = 5.26% (E(91.23b)/V(159.63b) * Re(8.58%)) + (D(68.40b)/V(159.63b) * Rd(1.12%) * (1-Tc(0.25)))
Shares Correlation 5-Years: -90.0 | Cagr: -1.26%
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 72.20% ; FCFE base≈4.98b ; Y1≈3.94b ; Y5≈2.62b
Fair Price DCF = 35.03 (DCF Value 44.43b / Shares Outstanding 1.27b; 5y FCF grow -24.86% → 3.0% )
Revenue Correlation: 92.94 | Revenue CAGR: 7.46%
Rev Growth-of-Growth: -1.50
EPS Correlation: 24.94 | EPS CAGR: 35.60%
EPS Growth-of-Growth: -74.05
Additional Sources for CVS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle